Type 2 Diabetes

Adults with type 2 diabetes who use statins have a lower risk for hip fracture than those who do not use statins, according to data published in Diabetes/Metabolism Research and Reviews.

In pregnancies with type 2 diabetes, metformin plus insulin did not reduce risks for adverse neonatal outcomes compared with placebo plus insulin, according to findings presented at The Pregnancy Meeting.

There are many benefits of time-restricted eating and many mechanisms that may play a role. It has been shown that time-restricted eating affects the gut microbiome. When we restrict our eating window to only a certain period during the day, it increases the diversity of the gut microbiome and also affects the composition. We know that our gut microbiome may affect our insulin sensitivity and our immune function, and it may have beneficial effects on our cardiovascular system.

About 50% of patients with gestational diabetes followed up with primary care in the first year postpartum, despite guidelines recommending universal follow up to improve health outcomes, according to results published in JAMA Network Open.

SGLT2 inhibitors were associated with a lower risk for major adverse cardiovascular events and heart failure hospitalization compared with DPP-4 inhibitors among patients with type 2 diabetes, regardless of baseline HbA1c levels, data show

A 12-month aerobic exercise program reduced the risk for type 2 diabetes among people with central obesity over 10 years, according to a study published in JAMA Internal Medicine.

About one-third of adults who were prescribed a GLP-1 receptor agonist to treat type 2 diabetes lost at least 5% of their body weight at 72 weeks, according to findings from a real-world retrospective analysis.

A brief alcohol-related intervention in people with unhealthy alcohol use was linked to reduction of diastolic BP in patients with hypertension but did not improve outcomes in patients with type 2 diabetes, researchers reported.

Adults with type 2 diabetes who use proton pump inhibitors have a higher risk for coronary artery disease, myocardial infarction, heart failure and all-cause mortality than nonusers, according to data from the UK Biobank.

With the availability of a medication that can delay the onset of type 1 diabetes, expanded screening for the disease has become more important, according to Richard Oram, MD, PhD.